Cargando…
Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD(−/−)) Mouse to Compensate a Defective Fatty Acid β-Oxidation
Very long-chain acyl-CoA dehydrogenase (VLCAD)-deficiency is the most common long-chain fatty acid oxidation disorder presenting with heterogeneous phenotypes. Similar to many patients with VLCADD, VLCAD-deficient mice (VLCAD(−/−)) remain asymptomatic over a long period of time. In order to identify...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443214/ https://www.ncbi.nlm.nih.gov/pubmed/23024820 http://dx.doi.org/10.1371/journal.pone.0045429 |
_version_ | 1782243527485292544 |
---|---|
author | Tucci, Sara Herebian, Diran Sturm, Marga Seibt, Annette Spiekerkoetter, Ute |
author_facet | Tucci, Sara Herebian, Diran Sturm, Marga Seibt, Annette Spiekerkoetter, Ute |
author_sort | Tucci, Sara |
collection | PubMed |
description | Very long-chain acyl-CoA dehydrogenase (VLCAD)-deficiency is the most common long-chain fatty acid oxidation disorder presenting with heterogeneous phenotypes. Similar to many patients with VLCADD, VLCAD-deficient mice (VLCAD(−/−)) remain asymptomatic over a long period of time. In order to identify the involved compensatory mechanisms, wild-type and VLCAD(−/−) mice were fed one year either with a normal diet or with a diet in which medium-chain triglycerides (MCT) replaced long-chain triglycerides, as approved intervention in VLCADD. The expression of the mitochondrial long-chain acyl-CoA dehydrogenase (LCAD) and medium-chain acyl-CoA dehydrogenase (MCAD) was quantified at mRNA and protein level in heart, liver and skeletal muscle. The oxidation capacity of the different tissues was measured by LC-MS/MS using acyl-CoA substrates with a chain length of 8 to 20 carbons. Moreover, in white skeletal muscle the role of glycolysis and concomitant muscle fibre adaptation was investigated. In one year old VLCAD(−/−) mice MCAD and LCAD play an important role in order to compensate deficiency of VLCAD especially in the heart and in the liver. However, the white gastrocnemius muscle develops alternative compensatory mechanism based on a different substrate selection and increased glucose oxidation. Finally, the application of an MCT diet over one year has no effects on LCAD or MCAD expression. MCT results in the VLCAD(−/−) mice only in a very modest improvement of medium-chain acyl-CoA oxidation capacity restricted to cardiac tissue. In conclusion, VLCAD(−/−) mice develop tissue-specific strategies to compensate deficiency of VLCAD either by induction of other mitochondrial acyl-CoA dehydrogenases or by enhancement of glucose oxidation. In the muscle, there is evidence of a muscle fibre type adaptation with a predominance of glycolytic muscle fibres. Dietary modification as represented by an MCT-diet does not improve these strategies long-term. |
format | Online Article Text |
id | pubmed-3443214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-34432142012-09-28 Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD(−/−)) Mouse to Compensate a Defective Fatty Acid β-Oxidation Tucci, Sara Herebian, Diran Sturm, Marga Seibt, Annette Spiekerkoetter, Ute PLoS One Research Article Very long-chain acyl-CoA dehydrogenase (VLCAD)-deficiency is the most common long-chain fatty acid oxidation disorder presenting with heterogeneous phenotypes. Similar to many patients with VLCADD, VLCAD-deficient mice (VLCAD(−/−)) remain asymptomatic over a long period of time. In order to identify the involved compensatory mechanisms, wild-type and VLCAD(−/−) mice were fed one year either with a normal diet or with a diet in which medium-chain triglycerides (MCT) replaced long-chain triglycerides, as approved intervention in VLCADD. The expression of the mitochondrial long-chain acyl-CoA dehydrogenase (LCAD) and medium-chain acyl-CoA dehydrogenase (MCAD) was quantified at mRNA and protein level in heart, liver and skeletal muscle. The oxidation capacity of the different tissues was measured by LC-MS/MS using acyl-CoA substrates with a chain length of 8 to 20 carbons. Moreover, in white skeletal muscle the role of glycolysis and concomitant muscle fibre adaptation was investigated. In one year old VLCAD(−/−) mice MCAD and LCAD play an important role in order to compensate deficiency of VLCAD especially in the heart and in the liver. However, the white gastrocnemius muscle develops alternative compensatory mechanism based on a different substrate selection and increased glucose oxidation. Finally, the application of an MCT diet over one year has no effects on LCAD or MCAD expression. MCT results in the VLCAD(−/−) mice only in a very modest improvement of medium-chain acyl-CoA oxidation capacity restricted to cardiac tissue. In conclusion, VLCAD(−/−) mice develop tissue-specific strategies to compensate deficiency of VLCAD either by induction of other mitochondrial acyl-CoA dehydrogenases or by enhancement of glucose oxidation. In the muscle, there is evidence of a muscle fibre type adaptation with a predominance of glycolytic muscle fibres. Dietary modification as represented by an MCT-diet does not improve these strategies long-term. Public Library of Science 2012-09-14 /pmc/articles/PMC3443214/ /pubmed/23024820 http://dx.doi.org/10.1371/journal.pone.0045429 Text en © 2012 Tucci et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Tucci, Sara Herebian, Diran Sturm, Marga Seibt, Annette Spiekerkoetter, Ute Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD(−/−)) Mouse to Compensate a Defective Fatty Acid β-Oxidation |
title | Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD(−/−)) Mouse to Compensate a Defective Fatty Acid β-Oxidation |
title_full | Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD(−/−)) Mouse to Compensate a Defective Fatty Acid β-Oxidation |
title_fullStr | Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD(−/−)) Mouse to Compensate a Defective Fatty Acid β-Oxidation |
title_full_unstemmed | Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD(−/−)) Mouse to Compensate a Defective Fatty Acid β-Oxidation |
title_short | Tissue-Specific Strategies of the Very-Long Chain Acyl-CoA Dehydrogenase-Deficient (VLCAD(−/−)) Mouse to Compensate a Defective Fatty Acid β-Oxidation |
title_sort | tissue-specific strategies of the very-long chain acyl-coa dehydrogenase-deficient (vlcad(−/−)) mouse to compensate a defective fatty acid β-oxidation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443214/ https://www.ncbi.nlm.nih.gov/pubmed/23024820 http://dx.doi.org/10.1371/journal.pone.0045429 |
work_keys_str_mv | AT tuccisara tissuespecificstrategiesoftheverylongchainacylcoadehydrogenasedeficientvlcadmousetocompensateadefectivefattyacidboxidation AT herebiandiran tissuespecificstrategiesoftheverylongchainacylcoadehydrogenasedeficientvlcadmousetocompensateadefectivefattyacidboxidation AT sturmmarga tissuespecificstrategiesoftheverylongchainacylcoadehydrogenasedeficientvlcadmousetocompensateadefectivefattyacidboxidation AT seibtannette tissuespecificstrategiesoftheverylongchainacylcoadehydrogenasedeficientvlcadmousetocompensateadefectivefattyacidboxidation AT spiekerkoetterute tissuespecificstrategiesoftheverylongchainacylcoadehydrogenasedeficientvlcadmousetocompensateadefectivefattyacidboxidation |